Rhythm Pharmaceuticals launches IMCIVREE in Japan as first approved therapy for acquired hypothalamic obesity

Rhythm Pharmaceuticals launched IMCIVREE in Japan as the first approved therapy for acquired hypothalamic obesity, backed by Phase 3 TRANSCEND trial data showing an 18.8% placebo-adjusted BMI reduction.

Detected & updated continuously · Source: Nebula